FDA Removes Misleading Warnings on Hormone Therapy: What It Really Means for Women
A Historic Shift for Women’s Health
For more than two decades, women have lived under a cloud of fear surrounding hormone replacement therapy (HRT). Labels on estrogen and estrogen-related products carried “black box” warnings — the FDA’s most serious caution — suggesting risks of heart disease, breast cancer, and dementia.
This week, that changed.
On November 10, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) announced the removal of these broad warnings.
(Read the FDA News Release →)
According to the agency, decades of follow-up research and expert review have shown that the original warnings were based on outdated data from the early 2000s Women’s Health Initiative (WHI) — a study whose average participant was 63 years old, long past the onset of menopause, and who received a hormone formulation no longer in common use.
What the FDA Removed
The FDA’s updated directive removes references to:
- Increased risk of cardiovascular disease (heart attack and stroke)
- Increased risk of breast cancer
- Risk of probable dementia
The agency will work with manufacturers to update product labels to reflect these changes.
The boxed warning for endometrial cancer remains for systemic estrogen-only therapy in women who still have a uterus — an important safety measure that continues to require the use of progesterone in combination therapy.
What the Science Actually Shows
Modern randomized studies now demonstrate that when hormone therapy is initiated within 10 years of menopause onset (or before age 60):
- All-cause mortality decreases
- Cardiovascular disease risk drops by up to 50 percent
- Alzheimer’s disease risk decreases by approximately 35 percent
- Fracture risk falls by 50–60 percent
These findings reaffirm that timing matters. Starting HRT in the right window — and using bio-identical or modern formulations under medical supervision — offers powerful protective effects across brain, bone, heart, and muscle health.
Restoring Evidence-Based Care
Health and Human Services Secretary Robert F. Kennedy Jr. summarized the decision succinctly:
“For more than two decades, bad science and bureaucratic inertia have resulted in women and physicians having an incomplete view of HRT. We are returning to evidence-based medicine and giving women control over their health again.”
FDA Commissioner Dr. Marty Makary echoed that sentiment, emphasizing that this change restores trust in women’s health data and encourages personalized decision-making between women and their physicians. Busting the myth and showing the evidence that estrogen does not causes breast cancer.
Why This Matters
This is more than a regulatory update — it’s a cultural reset.
For years, misinformation discouraged millions of women from accessing therapies that could improve quality of life and long-term health. The FDA’s move marks the beginning of a new era where data replaces dogma, and where the nuances of age, formulation, and timing are finally part of the conversation.
At Thrive for Longevity, we welcome this change. Our mission has always been to help women feel better, think clearer, and live longer — through science, community, and access to credible information.
Key Takeaways
- The FDA has removed black-box warnings linking HRT to cardiovascular disease, breast cancer, and dementia.
- Estrogen does not cause breast cancer.
- The warning for endometrial cancer remains for estrogen-only therapy in women with a uterus.
- When started within 10 years of menopause (or before age 60), HRT is associated with reductions in mortality, cardiovascular risk, and fractures.
- The decision reflects decades of new evidence correcting outdated conclusions from the WHI study.
Learn More
Full FDA Press Release:
HHS Advances Women’s Health — Removes Misleading FDA Warnings on Hormone Replacement Therapy
Evidence Reference List:
Available upon request — comment HRT on Instagram @thriveforlongevity or subscribe to our newsletter for access.
References
- U.S. Food and Drug Administration. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. Press Release, Nov 10 2025.
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333.
- Manson JE et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013;310(13):1353-1368.
- Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291(14):1701-1712.
- Salpeter SR et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791-804.
- Chlebowski RT et al. Estrogen plus progestin and breast cancer incidence and mortality in WHI trials. JAMA. 2010;304(15):1684-1692.
- Anderson GL et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy. Lancet Oncol. 2012;13(5):476-486.
- Shumaker SA et al. Estrogen and progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: WHI Memory Study. JAMA. 2003;289(20):2651-2662.
- Rocca WA et al. Long-term effects of estrogen therapy on cognitive aging and dementia risk: timing hypothesis revisited. Neurodegener Dis. 2011;8(5):496-503.
- Reginster JY et al. Prevention of postmenopausal bone loss by low doses of 17β-estradiol: a two-year randomized trial. Calcif Tissue Int. 1992;50(6):475-479.
- Anderson GL et al. Effects of estrogen therapy on fracture risk in the Women’s Health Initiative trial. Arch Intern Med. 2003;163(7):861-868.
- Harvey NC et al. Menopausal hormone therapy reduces fracture risk regardless of baseline FRAX fracture probability. Osteoporos Int. 2022;33:2297-2305.
- Zhao N et al. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. Open Life Sci. 2023;18(1).
- MHT in the management of osteoporosis: now more than ever. Maturitas. 2025.
- National Institutes of Health. Women’s Health Initiative 20-Year Follow-Up Summary. Bethesda, MD: NIH; 2023.
Thrive for Longevity | Evidence Over Fear · Science Over Speculation
